BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 14, 2026
Home » Topics » Analysis and data insight, BioWorld

Analysis and data insight, BioWorld
Analysis and data insight, BioWorld RSS Feed RSS

Biopharma money raised: Jan. 1-27, 2022

Jan. 28, 2022
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma: 2022 vs. 2021 vs. 2020 vs. 2019

Jan. 28, 2022
Total raised in public, private and other financings of biopharma companies, comparing 2022 vs. 2021 vs. 2020 vs. 2019.
Read More
Coronavirus and stock charts

As the world grows weary of COVID-19, so do infectious disease investors

Jan. 27, 2022
By Karen Carey
While BioWorld’s Infectious Disease Index showed a huge 144% climb in 2020, an enthusiastic response toward defeating the SARS-CoV-2 virus, the index dropped significantly in early 2021 and spent most of the year spiking up and down, reacting abruptly to the promises of herd immunity and the threats of vaccine-resistant variants.
Read More
Syringe and capsules atop lab chart

Despite a busy 2021, clinical data slows to pre-pandemic levels

Jan. 25, 2022
By Karen Carey
The amount of clinical data reported in January so far is currently 30% below the amount reported during the same month last year, which was the slowest month of 2021.
Read More

Biggest gainers and losers for the week of Jan. 17-21, 2022

Jan. 21, 2022
The top 10 biopharma stock gainers and losers for the week.
Read More

Biopharma money raised: Jan. 1-20, 2022

Jan. 21, 2022
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma: 2022 vs. 2021 vs. 2020 vs. 2019

Jan. 21, 2022
Total raised in public, private and other financings of biopharma companies, comparing 2022 vs. 2021 vs. 2020 vs. 2019.
Read More

Biggest gainers and losers for the week of Jan. 10-14, 2022

Jan. 14, 2022
The top 10 biopharma stock gainers and losers for the week.
Read More

Biopharma money raised: Jan. 1-13, 2022

Jan. 14, 2022
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma: 2022 vs. 2021 vs. 2020 vs. 2019

Jan. 14, 2022
Total raised in public, private and other financings of biopharma companies, comparing 2022 vs. 2021 vs. 2020 vs. 2019.
Read More
Previous 1 2 … 145 146 147 148 149 150 151 152 153 … 242 243 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 12, 2026.
  • Purple molecules

    Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

    BioWorld
    Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
  • Neck exam

    Ethyreal launches to treat the underlying cause of Graves’, TED

    BioWorld
    Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
  • 3D illustration of a nerve cell

    Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

    BioWorld
    Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
  • Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists

    BioWorld Science
    Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing